In people with type 2 diabetes, taking PCSK9 inhibitors for three years does not lead to a meaningful increase in blood sugar levels or HbA1c, indicating no negative impact on diabetes control.

Pro

Against

Mechanism

Synthesis from 1 study

How it works

These drugs lower cholesterol by helping the liver clean up more of it from the blood, but they don't harm the pancreas cells that make insulin in people who already have type 2 diabetes. That's why their blood sugar stays steady over time.

Most probable mechanism

In Simple Terms

Drugs that block PCSK9 help the liver remove more cholesterol from the blood, but this doesn't cause the insulin-producing cells in the pancreas to take in too much cholesterol or stop working properly in people who already have type 2 diabetes, so their blood sugar stays stable.

Causal chain

PCSK9 inhibitors bind to circulating PCSK9 protein, preventing it from degrading low-density lipoprotein receptors on hepatocytes

Supported by evidence

which leads to

Increased low-density lipoprotein receptor expression on hepatocytes enhances clearance of low-density lipoprotein cholesterol from the bloodstream

Supported by evidence

which leads to

Despite theoretical potential for increased low-density lipoprotein receptor expression on pancreatic beta-cells, no measurable increase in intracellular cholesterol accumulation or beta-cell dysfunction occurs in individuals with pre-existing type 2 diabetes

Supported by evidence

which leads to

Insulin secretion capacity and beta-cell viability remain unchanged, resulting in stable fasting glucose and HbA1c levels over time

Supported by evidence

Evidence from Studies

Supporting (1)

Community contributions welcome

Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes

Cohort Study

Human

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes

Score: 56

DOI: 10.1186/s12933-023-02077-y

Similar Assertions

In adults taking PCSK9 inhibitors, higher fasting glucose levels before treatment are linked to a greater chance of developing type 2 diabetes, with each 1 mg/dL increase corresponding to a 10% higher odds, regardless of age, body weight, statin use, or cholesterol changes.

82%

In adults with prediabetes, long-term use of PCSK9 inhibitors may be linked to a slight increase in the rate of developing type 2 diabetes compared to those not taking these drugs, but the difference is not large enough to be considered clinically meaningful, and overall glucose metabolism is not significantly affected.

79%

People who naturally have lower activity of a protein called PCSK9 don’t seem to have a higher chance of getting type 2 diabetes — which means drugs that target PCSK9 might not increase diabetes risk like some earlier studies worried they would.

78%

In people with prediabetes and heart disease, taking evolocumab for about two years does not increase the risk of developing diabetes, based on measurements of blood sugar levels and diabetes incidence over time.

76%